JHP/SpePharm acquire rights to Dantrium
The USA's JHP Pharmaceuticals and Dutch drug company SpePharm have together acquired global rights to health care major Procter and Gamble's Dantrium (dantrolene sodium). In its intravenous form, the drug is used for malignant hyperthermia, a life-threatening reaction to certain gaseous anesthetics, and in its oral form, the control of clinical spasticity resulting from upper motor neuron disorders.
New Jersey-based JHP has bought the rights to Dantrium for the USA and Canada, including supply rights in Australia, New Zealand, Israel and Chile, while SpePharm acquired the rights in the rest of the world.
Stuart Hinchen, president of JHP, said: "this product will fit well into our current portfolio of marketed products which already includes exports to Canada and Australia."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze